X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IM-101 is a humanized monoclonal antibody targeting complement C5, which plays a pivotal role in complement activation. It is being evaluated for the treatment of autoimmune diseases.
Lead Product(s): IM-101
Therapeutic Area: Immunology Product Name: IM-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH).
Lead Product(s): IM-101
Therapeutic Area: Rare Diseases and Disorders Product Name: IM-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
